The text starts here.

News Release

FOR IMMEDIATE RELEASE
May 20, 2011

EISAI ONCOLOGY TO PRESENT NEW RESEARCH ON PRODUCT PORTFOLIO, PIPELINE AT ASCO ANNUAL MEETING

May 20, 2011
Eisai Co., Ltd.

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today that 19 abstracts highlighting new study results on thyroid cancer, acute myeloid leukemia, metastatic breast cancer, ovarian cancer and other cancers will be presented during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, United States, from June 3 to June 7, 2011.

These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's commitment to address the diverse needs of patients and their families affected by cancer.

Eisai's commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, biologics chemotherapies and supportive care agents for cancer across multiple indications. Through these efforts, Eisai will make further contributions to addressing the diversified needs of and increasing the benefits provided to patients and their families as well as healthcare professionals as it seeks to fulfill its human health care (hhc) mission.


 The following Eisai abstracts are accepted for presentation at this year's ASCO meeting:
  Product Abstract Details
1 Lenvatinib
(E7080)
Abstract No:5503
A Phase II Trial of the Multi-Targeted Kinase Inhibitor E7080 in Advanced Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer (DTC)
Oral Session
2 Lenvatinib
(E7080)
Abstract No:8527
Assessment of Clinical Activity of E7080, a Multi-Targeted Kinase Inhibitor, in Patients with Advanced Melanoma Treated in Two Phase I trials
Poster discussion session
3 Lenvatinib
(E7080)
Abstract No: 8566
The Effect of E7080, a VEGFR and FGFR Tyrosine Kinase Inhibitor (TKI), on BRAF Wild-Type Melanoma
Poster Session
4 Lenvatinib
(E7080)
Abstract No:8567
Mechanism of Antitumor Activity of E7080, a Selective VEGFR and FGFR Tyrosine Kinase Inhibitor (TKI) in Combination with Selective Mutant BRAF Inhibition
Poster Session
5 Lenvatinib
(E7080)
Abstract No:8595
Molecular profiling of melanoma tumor biopsies to identify a response signature to the multi-RTK inhibitor, E7080
Poster Presentation
6 Farletuzumab
(MORAb-003)
Abstract No:5056
Phase I Safety Study of Farletuzumab, Carboplatin and Peglyated Liposomal Doxorubicin (PLD) in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer (EOC)
Poster Session
7 MORAb-004
Abstract No:3086
A First-in-Human Phase I Study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors
Poster Session
8 Decitabine for Injection
Abstract No: 6504
Results from a Randomized Phase III Trial of Decitabine Versus Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed AML
Oral Session
9 Decitabine for Injection
Abstract No:6551
Population Pharmacokinetic modeling of Decitabine in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Poster Session
10 Decitabine for Injection
Abstract No:6552
Healthcare utilization and costs in patients with early onset myelodysplastic syndrome in a commercially insured population
Poster Session
11 Decitabine for Injection
Abstract No:6560
Relationship Between Age and Healthcare Utilization in Patients with Myelodysplastic Syndrome Receiving Supportive Care
Poster Session
12 Decitabine for Injection
Abstract No:6598
Retrospective Analysis of Prognostic Factors Associated with Response and Overall Survival in Patients with RAEB-t MDS treated with Decitabine
Poster Session
13 Decitabine for Injection
Abstract No:6600
Retrospective analysis of effects of dose modification and myelosuppression on response to decitabine and overall survival in patients with myelodysplastic syndromes.
Poster Session
14 Decitabine for Injection
Abstract No:6617
Retrospective Analysis of Effects of Transfusion Status on Response to Decitabine and Survival in Patients with Myelodysplastic Syndromes
Poster Session
15 Eribulin Mesylate
Abstract No: 1060
The Relationship Between Age and Survival Outcomes for Eribulin in Metastatic Breast Cancer
Poster Session
16 Eribulin Mesylate
Abstract No: 2544
Eribulin Dosing in Patients with Advanced Solid Tumors and Hepatic Impairment
Poster Session
17 Palonosetron
Hydrochloride
Abstract No:9091
Analysis of Phase III Clinical Studies for Palonosetron, Ondansetron, Dolasetron and Granisetron in the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Poster Session
18 Palonosetron
Hydrochloride
Abstract No:6068
Willingness to Pay to Prevent Chemotherapy Induced Nausea and Vomiting
Poster Session
19 Polifeprosan 20 with
carmustine implant
Abstract No:2015
Effects of Surgery with BCNU Wafer Placement on Neurocognitive Function in Patients with One to Three Brain Metastases
Poster Discussion

Decitabine = Dacogen®、Eribulin Mesylate = Halaven®、Palonosetron Hydrochloride = Aloxi®、Polifeprosan 20=Gliadel® Wafer

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120